Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition
The acquisition of breakout obesity star Metsera should pump new life into Pfizer’s portfolio, which over the last two years has suffered from three discontinued assets.
Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition Read More »
